SonALAsense is a clinical-stage company developing ALA sonodynamic therapy (SDT) as a first-in-class, non-invasive drug-device combination for the treatment of recurrent glioblastoma multiforme (rGBM) and other deadly cancers. SDT utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells.
| Website | https://sonalasense.com/ |
| Employees | 10 (7 on RocketReach) |
| Founded | 2019 |
| Phone | +1 510-831-2220 |
| Technologies |
JavaScript
,
HTML
,
PHP
+13 more
(view full list)
|
| Industry | Biotechnology Research, Therapeutic Devices, Drug Delivery |
| Keywords | Cancer Treatment, Oncology, Cancer Research, Drug Delivery, Brain Cancer, Medical Devices, Immunotherapy, Non Invasive Therapy, Biotechnology, Clinical Trials, Targeted Therapy, Precision Medicine, Radiotherapy, Innovative Cancer Therapies |
| Competitors | BrainCo_Tech, MindMaze, EMOTIV, InteraXon Inc., Advanced Brain Monitoring, NeuroSky, OpenBCI, 浙江诺尔康神经电子科技股份有限公司, Cognionics, Inc., Foc.us Electrical Brain Stimulators +20 more (view full list) |
Looking for a particular SonALAsense employee's phone or email?
Mark de Souza is the President and CEO of SonALAsense.
7 people are employed at SonALAsense.
SonALAsense is based in Oakland, California.